Clementia Pharmaceuticals Inc. (CMTA) Is Rising On FDA News

Clementia Pharmaceuticals Inc. (CMTA) announced after the bell Tuesday that based on the results of a Phase 2 study, as well as a meeting with the FDA, it plans to submit a New Drug Application for palovarotene in the second half of 2019. The stock is now up 3.43 on 217K shares.

Clementia Pharmaceuticals moved in a narrow range throughout Tuesday's session and closed up by 0.61 at $10.34.